Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Inclusion Criteria12

• A biopsy proven histological diagnosis of rectal adenocarcinoma；
• An ARMS-PCR proven KRAS, NRAS mutation, excluding BRAF mutation or microsatellite instablility-High;
• No intestinal obstruction, distant metastasis was excluded by CT, MRI or PET / CT;
• MRI proven T3c-T4, CRM positive, N2, extramural vascular invasion positive or lateral lymph node positive of locally advanced rectal cancer;
• Age between 18-75 years;
• ECOG (Eastern US Cooperative Oncology Group) score: 0-1;
• Has sufficient organ function:
• Hemopoietic function: hemoglobin ≥ 90 g / L, platelet ≥ 80 g / L × 109 / L,
• neutrophils ≥ 1.5 × 109/L
• Liver function: ALT and AST \< 2.5 × ULN;
• Renal function: serum creatinine \< 1.5 ULN;
• Willing to participate and informed consent signed；